Physician profile
Anthony Ashkar
NPI 1376862417
$2,103.67
in general payments reported to CMS, 2019-2025
13 companies · $372 in 2025
The $372 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $47.66 · 2021: $223 · 2022: $375 · 2023: $395 · 2024: $465 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,231.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $721.69 | 2022-2025 | Airsupra, Tagrisso, Breztri |
| Daiichi Sankyo INC. | $352.44 | 2019-2023 | Injectafer |
| Glaxosmithkline, LLC. | $267.86 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Mylan Specialty L.P. | $169.90 | 2022-2024 | Yupelri |
| Intuitive Surgical, INC. | $154.52 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.46 | 2020-2022 | |
| Lilly USA, LLC | $107.41 | 2025 | Zepbound |
| Genzyme Corporation | $107.07 | 2025 | |
| Baxter Healthcare | $22.50 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Inogen, INC. | $21.52 | 2025 | |
| Grifols USA, LLC | $19.08 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $18.76 | 2024 | Opsumit |
| Regeneron Healthcare Solutions, INC. | $17.46 | 2025 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Ashkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.